What's New/
Latest news
- All
- Advocacy
- Experiences
- Guest Blog
- Information
- Research
- Reviews
- All
- Advocacy
- Experiences
- Guest Blog
- Information
- Research
- Reviews
Information Holidays start – and along comes a migraine attack
It’s a familiar story – the end of the year, finishing up at work, rushing ...
Read More
Information The power of a crystal-clear day
Migraine attacks come in phases for many people. They start with a constellation of possible ...
Read More
Advocacy Emgality advocacy toolkit launched
At the end of November, we submitted a consumer application to Pharmac to fund Emgality ...
Read More
Advocacy Migraine Foundation submits application to Pharmac to fund Emgality
Press release Migraine Foundation Aotearoa New Zealand has submitted a consumer application to Pharmac to ...
Read More
Reviews Managing Your Migraine: Book review
Dr Katy Munro from the National Migraine Centre in the UK published a book in ...
Read More
Reviews The Painful Truth: Book review
The Painful Truth: The New Science of Why We Hurt and How We Can Heal. ...
Read More
Research New Zealand health survey data – a decade to be released
Have you ever been told by a doctor you have migraines [sic]? This is what ...
Read More
Information Biofeedback: an underused migraine treatment
There’s a treatment for migraine that is safe, has no side effects and may work ...
Read More
Experiences I tried Aimovig for six months. Here’s my verdict
Calcitonin gene-related peptide or CGRP for short. That’s the target of most of the new ...
Read More
Information Anxiety and migraine
Do you have trouble relaxing? Are you unable to control or stop worrying? Feel nervous, ...
Read More
Information Emgality Frequently Asked Questions (FAQs)
In September 2022, the second calcitonin gene-related monoclonal (CGRP) monoclonal antibody medication called Emgality (galcanezumab) ...
Read More
Information The link between migraine and depression
For Mental Health Awareness Week, we want to highlight that people with migraine disease are ...
Read More
